biotech stocks

Just because CSL hadn’t factored in financial benefit from CSL112, it doesn’t mean the market hadn’t.

It's a challenging time for growth investors. Plenty of fund managers have posted negative returns, but Michael Frazis remains optimistic. In this wire he, spells out...

Sector Overview The IIR Pharma & Biotech Index increased 2.9% in the month of June, in line with the broader market with the ASX All Ordinaries Accumulation Index up...

It hasn’t been a good year for Avita Therapeutics (ASX:AVH). The med-tech stock is the worst performer among Livewire readers’ 10 most-tipped small caps, down nearly...

Both IXC and PAR (Paradigm Biopharmaceuticals) are repurposing existing drugs, successfully completed Phase II trials, completed recent capital raises (both...